Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular Testingpriority health genetics coverage & Prior Auth | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy N/A

    Genetics: Counseling, Testing, Screening

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage criteria for genetic counseling, testing, and screening services for Priority Health members, including medical necessity, prior authorization, and services managed through eviCore. Applies to providers ordering or performing genetic services for affected members.

    Policy Summary
    Payerpriority health
    PolicyGenetics: Counseling, Testing, Screening
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain electronic prior authorization through Evicore for tests listed as eC PA before billing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    EvicoreEvicore managed
    Counselor reqBoard-certified counselors required
    rWGSrWGS criteria
    ExclusionsNon-covered examples
    ~150+
    CPT/HCPCS codes referenced

    Coverage Criteria

    I. MEDICAL NECESSITY CRITERIA

    Genetic counseling, testing and prenatal genetic services — Coverage is determined by the following medical necessity criteria and exclusions.

    Appropriate genetic counseling occurs before and after testing.

    Counseling must be performed by a board-certified genetic counselor independent of the testing laboratory for specified conditions (see Appendix A). Counseling may occur at the same visit as sample collection with documentation.

    Documented informed consent occurs before testing.

    Michigan law requires informed consent for predictive genetic testing (Public Health Code Act 368 of 1978: Sec. 333.17020).

    Prior authorization is obtained when required.

    Selected tests require prior authorization via Evicore. See Section VI (Coding) and Evicore guidelines via Priority Health Prism -> Authorizations -> Authorization Criteria Lookup.

    Tumor chemoresistance/chemosensitivity assays

    • Tumor in vitro chemoresistance and chemosensitivity assays are considered experimental, investigational, and not medically necessary for brain tumors/brain metastases (eg, 3D Predict Glioma).
    • Tumor in vitro chemoresistance and chemosensitivity assays are considered experimental, investigational, and not medically necessary for breast cancer (eg, Theralink Reverse Phase Protein Array).
    • Other in vitro chemoresistance/chemosensitivity assays are vendor-managed via Evicore.

      Refer prior authorization to Evicore for determination.

    General coverage statements

    • Genetic carrier screening, gene expression analysis, predictive genetic testing, pharmacogenomic testing, prognostic testing, and diagnostic testing for suspected genetic conditions may be medically necessary according to Evicore guidelines.
    • Whole genome sequencing (WGS), whole exome sequencing (WES), mitochondrial whole genome analysis, and genome-wide association studies conducted in the outpatient setting may be medically necessary per Evicore.

    E. Prenatal Testing

    Prenatal testing, NIPT, diagnostic invasive testing, rWGS and selected prenatal-related exclusions and conditions.

    ALL of the following

    • Appropriate education and genetic counseling occurs prior to testing.
    • Pregnancy is singleton or twin.
    • Gestational age is within the testing laboratory's validated window.
    Cell-free DNA screening for sex chromosomes (X and Y) or less common trisomies are not separately payable.
    Prenatal cfDNA screening for chromosome microdeletions or single-gene mutations is considered investigational/experimental and not medically necessary.

    M. Rapid Whole Genome Sequencing (rWGS)

    Rapid Whole Genome Sequencing (rWGS) — inpatient pediatric use criteria and notification requirement.

    ALL of the following

    • Ordered after determination by a Board-Certified or Board-Eligible Medical Geneticist that testing could be useful in establishing a diagnosis and treatment options.
    • Member is less than 18 years of age.
    • Clinical timing

      • Tested within 1 week of admission to the hospital.
      • Tested within 1 week of development of an abnormal response to standard therapy for an underlying condition.
    Priority Health requires notification of intent to perform inpatient rapid WGS via the Genetics medical policy prior notification form; this may occur prior to or in conjunction with testing to avoid delays to inpatient care.

    inv-165: Per-code / Per-test Coverage and Dispositions

    Per-code and per-test coverage dispositions and prior authorization (eC PA) requirements. The following summarizes representative CPT, HCPCS, and U-code tests with their coverage category and any specific conditions.

    Per-code coverage actions and conditions

    • Codes designated 'eC PA' require electronic prior authorization via the eC/ Evicore process before testing is performed.
    • Codes designated 'No PA required' or 'OOS for eC - No PA required' do not require prior authorization but remain subject to medical necessity documentation and any line-of-business limitations.
    • Codes designated 'Not Covered' are considered not medically necessary and should not be billed for those lines of business; see per-code listing for applicable codes and any diagnosis limitations (eg, bladder tumor markers covered only for specified bladder neoplasm ICD-10 codes).

    Coverage dispositions (examples)

    • Many single-gene and panel tests (eg, BRCA1/BRCA2 [81162], APC [81201-81203], MLH1/MSH2/MSH6/PMS2 series [81288, 81292-81300, etc.], and numerous 8xx/81xxx codes) are listed as eC PA across commercial, Medicaid, and Priority Medicare lines.

    inv-166/167/168/169/170: Gene-specific Panels, Minimal Gene Sets, and eC PA vs Not Covered Stances

    Gene-specific, panel-specific and specialty-area coverage stances including minimal gene set expectations and eC PA vs Not Covered distinctions.

    Gene/panel coverage stance

    • Disease- or phenotype-specific panels (eg, cardiac ion channelopathies 81413/81414, epilepsy 81419, hearing loss 81430/81431, hereditary breast/ovarian 81432/0129U/0102U, hereditary colon cancer 81435/0101U/0102U, inherited cardiomyopathy 81439, nuclear-encoded mitochondrial gene panel 81440, IBMFS 81441, Noonan spectrum 81442) are generally designated eC PA; panels must meet minimal gene-set composition defined in the code description.
    • Mitochondrial genome sequencing and comprehensive exome/genome tests (eg, 81460, 81415, 81425) are typically eC PA and require documentation of clinical indication; rapid genome/sequencing U-codes (0094U/81415 equivalents) are eC PA with special inpatient pediatric criteria for rWGS.
    • Pharmacogenomic single-gene tests and panels (eg, CYP2D6-related U-codes 0072U-0074U, TPMT 81335, UGT1A1 81350, NUDT15 81306) are commonly eC PA; specific gene tests used for drug metabolism are subject to PA per code table.

    Coding and Test Codes

    Genetic CounselingCPTCovered
    96041Medical genetics and genetic counseling services, each 30 minutes of total time provided by the genetic counselor on the date of the encounter
    S0265Genetic counseling, under physician supervision, each 15 minutes
    Listed molecular and genetic CPT codesCPT
    81234DMPK (DM1 protein kinase) gene analysis; evaluation to detect abnormal (expanded) alleles
    81235EGFR gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)
    81236EZH2 gene analysis, full gene sequence
    81237EZH2 gene analysis, common variant(s) (eg, codon 646)
    81238F9 (coagulation factor IX) full gene sequence
    81239DMPK gene analysis; characterization of alleles (eg, expanded size)
    81240F2 (prothrombin) gene analysis, 20210G>A variant
    81241F5 (Factor V) gene analysis, Leiden variant
    81242FANCC gene analysis, common variant (eg, IVS4+4A>T)
    81243FMR1 gene analysis; evaluation to detect abnormal (eg, expanded) alleles
    1–10 of 46
    1/5
    Listed CPT Codes and Descriptions (extensive list)CPT
    81302MECP2 gene analysis; full sequence analysis
    81303MECP2 known familial variant
    81304MECP2 duplication/deletion variants
    81305MYD88 p.Leu265Pro (L265P) variant
    81306NUDT15 gene analysis, common variant(s)
    81307PALB2 full gene sequence
    81308PALB2 known familial variant
    81309PIK3CA targeted sequence analysis (eg, exons 7,9,20)
    81310NPM1 exon 12 variants
    81311NRAS gene analysis, variants in exon 2 and 3
    1–10 of 55
    1/6
    Detailed CPT codes and descriptions (chunks 54-73)CPT
    81400Molecular pathology procedure, Level 1
    81401Molecular pathology procedure, Level 2
    81402Molecular pathology procedure, Level 3
    81403Molecular pathology procedure, Level 4
    81404Molecular pathology procedure, Level 5
    81405Molecular pathology procedure, Level 6
    81406Molecular pathology procedure, Level 7
    81407Molecular pathology procedure, Level 8
    81408Molecular pathology procedure, Level 9
    81411Aortic dysfunction duplication/deletion analysis panel
    1–10 of 27
    1/3
    Listed CPT/PLA Codes and descriptions (chunks 90-109)CPT
    81464Solid organ neoplasm, cfDNA panel with comprehensive analysis (DNA/RNA, CNV, MSI, TMB, rearrangements)
    81465Whole mitochondrial genome large deletion analysis panel
    81470X-linked intellectual disability (XLID) panel
    81490(Code referenced in list)
    81493Coronary artery disease, mRNA, gene expression profiling of 23 genes
    81500Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4) with algorithm
    81503Oncology (ovarian), biochemical assays of five proteins with algorithm
    81504Oncology (tissue of origin), microarray gene expression profiling >2000 genes
    81507Fetal aneuploidy DNA sequence analysis of selected regions using maternal plasma
    81508Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG)
    1–10 of 18
    1/2
    Test Codes and Coverage NotesHCPCS
    0002M(PLA/Mol test code)
    0003M(PLA/Mol test code)
    0004M(PLA/Mol test code)
    0006M(PLA/Mol test code)
    0007M(PLA/Mol test code)
    0001U(PLA/Proprietary test code)
    0018U(PLA/Proprietary test code)
    0019U(PLA/Proprietary test code)
    0022U(PLA/Proprietary test code)
    0023U(PLA/Proprietary test code)
    1–10 of 11
    1/2
    PLA/Proprietary CodesHCPCS
    0060U(Proprietary PLA code)
    0067U(Proprietary PLA code)
    0075U(Proprietary PLA code)
    0076U(Proprietary PLA code)
    0084U(Proprietary PLA code)
    0089U(Proprietary PLA code)
    0111U(Proprietary PLA code)
    0113U(Proprietary PLA code)
    0114U(Proprietary PLA code)
    0120U(Proprietary PLA code)
    Tests and coverage statuses (multiple codes)mixed
    0211UOncology (pan-tumor), DNA and RNA by NGS, interpretative report for SNV, CNV, TMB, MSI
    0244UOncology (solid) comprehensive genomic profiling, 257 genes
    0252UFetal aneuploidy STR comparative analysis, POC
    0253UEndometrial receptivity analysis, RNA gene expression profile
    Listed U-codes and descriptions (chunks 162-181)HCPCS
    0239UTargeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, 311+ genes (FoundationOne Liquid CDx)
    0242UTargeted genomic sequence analysis panel, cfDNA 55-74 genes (Guardant360 CDx)
    0260UIdentification of CNVs by optical genome mapping
    0262UOncology gene expression profiling by RT-PCR of 7 gene pathways
    0264UOptical genome mapping (Praxis)
    0265UWhole genome and mitochondrial DNA sequence analysis (Praxis Whole Genome)
    0266UTissue-specific gene expression by whole-transcriptome
    0267UOptical genome mapping and whole genome sequencing combined
    0268UHematology aHUS genomic sequence analysis of 15 genes
    0269UAutosomal dominant congenital thrombocytopenia genomic sequence analysis of 14 genes
    1–10 of 15
    1/2
    Listed PLA/CPT Codes and Descriptions (chunks 180-199)mixed
    0407UCKD risk algorithm (IntelxDKD) - Not Covered
    0409UOncology (solid), DNA (80) and RNA (36) NGS from plasma
    0411UPsychiatry genomic analysis panel including CYP2D6 CNV
    0477UPharmacogenomic genotyping of 14 genes including CYP2D6 CNV
    0481UIDH1, IDH2, and TERT promoter NGS (tumor)
    0485UCell-free DNA and RNA NGS with interpretative report (Caris Assure)
    0486UTumor methylation markers in cfDNA (Northstar Response)
    Test Codes and Descriptions (chunks 216-235)HCPCS
    0478UOncology (NSCLC), digital PCR of 9 genes in FFPE tissue
    0485UCell-free DNA/RNA NGS with interpretative report
    0555UGenetic PGT-SR Plus embryonic genomic analysis per embryo
    0560UMRD baseline genomic sequence analysis, cfDNA
    0561UMRD subsequent cfDNA assessment
    0562UTargeted cfDNA panel, 33 genes (plasma)
    Listed U-codes and related CPT codes (chunks 234-253)HCPCS
    0555UGenetic assessment PGT-SR Plus per embryo
    0566UWhole-genome sequence combination of short and long reads for rare diseases
    0567UWhole-genome combination short and long reads Genomic Unity® 2.0
    0569UTumor methylation markers in cfDNA (Guardant Reveal)
    Laboratory and cytology/molecular codesCPT
    82172Apolipoprotein, each
    83006Growth stimulation expressed gene 2 (ST2)
    83950Oncoprotein; HER-2/neu
    83951Oncoprotein; des-gamma-carboxy-prothrombin (DCP)
    83993Calprotectin, fecal
    84233Receptor assay; estrogen
    84234Receptor assay; progesterone
    86152Cell enumeration using immunologic selection (eg, circulating tumor cells)
    86153Cell enumeration interpretation and report
    86294Immunoassay for tumor antigen, qualitative (eg, bladder tumor antigen)
    1–10 of 18
    1/2
    Cytology/flow cytometry/chromosome codesCPT
    88121Cytopathology, in situ hybridization, urinary tract specimen (UroVysion)
    88130Sex chromatin identification; Barr bodies
    88182Flow cytometry, cell cycle or DNA analysis
    88184Flow cytometry, cell surface, technical component; first marker
    88185Flow cytometry each additional marker
    88187Flow cytometry interpretation; 2 to 8 markers
    88189Flow cytometry interpretation; 16 or more markers
    88230Tissue culture for non-neoplastic disorders; lymphocyte
    88233Tissue culture for non-neoplastic disorders; skin or other solid tissue biopsy
    88235Tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells
    Chromosome analysis and molecular cytogeneticsCPT
    88241Thawing and expansion of frozen cells, each aliquot
    88245Chromosome analysis for breakage syndromes; baseline SCE, 20-25 cells
    88248Chromosome analysis for breakage syndromes; baseline breakage, score 50-100 cells
    88249Chromosome analysis for breakage syndromes; score 100 cells, clastogen stress
    88261Chromosome analysis; count 5 cells, 1 karyotype
    88262Chromosome analysis; count 15-20 cells, 2 karyotypes
    88263Chromosome analysis; count 45 cells for mosaicism
    88264Chromosome analysis; analyze 20-25 cells
    88267Chromosome analysis, amniotic fluid or chorionic villus, count 15 cells
    88271Molecular cytogenetics; DNA probe, each (eg, FISH)
    1–10 of 20
    1/2
    Pathology / ISH / unlisted procedure codesCPT
    88360Morphometric analysis, tumor immunohistochemistry, manual
    88361Morphometric analysis, tumor immunohistochemistry, computer-assisted
    88363Examination and selection of retrieved archival tissue(s) for molecular analysis
    88364In situ hybridization, per specimen; each additional single probe stain
    88365In situ hybridization, each probe
    88366In situ hybridization, per specimen; each multiplex probe stain
    88367Morphometric analysis, ISH, computer-assisted; initial single probe
    88368Morphometric analysis, ISH, manual, per specimen; each probe
    88369Morphometric analysis, ISH, manual; each additional single probe
    88373Morphometric analysis, ISH, computer-assisted; each additional single probe
    1–10 of 15
    1/2
    Reproductive/genetic counseling related codesCPT
    89290Biopsy, oocyte polar body or embryo blastomere, microtechnique; ≤5 embryos (Covered only with Fertility Rider)
    89291Biopsy, oocyte polar body or embryo blastomere, microtechnique; >5 embryos (Covered only with Fertility Rider)
    G9143Warfarin responsiveness testing by genetic technique

    Provider Actions and Prior Authorization

    Prior Authorization

    Evicore prior authorization required

    Selected genetic tests require prior authorization administered through Evicore; providers must obtain prior authorization via the Priority Health Prism Evicore workflow before ordering tests that are designated eC PA. See Section VI (Coding) for specific CPT/PLA codes that require Evicore PA.

    • Access Evicore: Priority Health Prism → Authorizations → Authorization Criteria Lookup
    Prior Authorization

    Check Evicore PA / panel-review status for listed codes

    Many molecular and genetic CPT/PLA codes in the coding tables are designated 'eC PA' or 'Review in panels' and therefore require prior authorization or panel-level review through Evicore when applicable; check each code's line-of‑business disposition before ordering.

    Note

    Not Covered — Exclusions and Explicit Non-Coverage

    Prenatal cfDNA screening for sex chromosome aneuploidy, microdeletions, and single‑gene mutation screening are explicitly called out as investigational or not separately payable. The policy makes cfDNA testing for trisomies 21, 13, and 18 medically necessary under counseling and lab‑validated gestational age criteria, but states that cfDNA screening for sex chromosomes, less common trisomies, microdeletions, and single‑gene prenatal mutation screening are not covered or investigational/experimental.

    The policy provides numerous examples of U‑codes and other proprietary codes designated Not Covered for certain payer lines; examples in the early U‑code window include 0008U, 0009U, 0010U, 0016U, 0017U and other U‑codes that are labeled Not Covered for Commercial, Medicaid, and Priority Medicare in the coding tables.

    Additional examples of tests explicitly listed as Not Covered in specific code windows include U‑codes such as 0078U (pain management genotyping panel), 0086U (Accelerate PhenoTest BC kit), 0112U/0115U (selected infectious or respiratory panels), and other U‑codes and CPT entries shown as Not Covered for one or more plan types in the coding tables.

    Many single‑gene blood group genotyping procedures and multiple Variantyx‑branded single‑gene or small‑panel analyses are listed with Not Covered status for Commercial and Medicaid plans (examples include 0180U–0183U and a range of 0212U–0238U entries). Providers should confirm the code‑level coverage stance before ordering blood group or related single‑gene tests.

    The multianalyte risk score test 81506 (PreDx Diabetes Risk Score) is explicitly listed as Not Covered for Commercial, Medicaid, and Priority Medicare in the coding table.

    Definitions and Background

    Genetic counseling interprets family and medical history, educates about inheritance patterns and testing options, and addresses psychosocial and ethical considerations. Counseling is required both before and after testing; for certain tests the policy requires counseling be performed by a board‑certified genetic counselor independent of the testing laboratory and that informed consent be documented in accordance with state law.

    Genetic counseling — definition & requirements
    DefinitionGenetic counseling: process helping individuals/families understand and adapt to medical, psychological, and familial implications of genetics, including interpretation of family/medical histories, education on inheritance and testing, and pre-/post-test psychosocial counseling.
    Provider qualificationGenetic counselors defined as ABMG or ABGC-certified physicians or masters/doctoral-level genetic counseling professionals trained at accredited institutions.
    Documentation requiredPre‑ and post‑test counseling and documented informed consent are required before testing; counseling can be by a physician specialist where indicated.
    Scope of counselingIncludes discussion of inheritance, testing options, management, prevention, resources, research, and ethical/legal/privacy implications.

    Coding — Key Values & Constraints

    rWGS patient age and related rWGS requirements
    Age thresholdrWGS (rapid whole genome sequencing) eligibility includes: member < 18 years of age.
    Ordering requirementrWGS must be ordered after determination by a Board‑Certified or Board‑Eligible Medical Geneticist that testing could be useful.
    Timing for acutely ill inpatientsTesting must occur within 1 week of admission or within 1 week of development of abnormal response to standard therapy for an acutely ill inpatient member.
    Procedure code panel PA trigger
    Trigger ruleIf any procedure code included in a multi‑test panel requires prior authorization, that procedure code should initiate Evicore prior authorization via the provider portal.
    Panel reporting note

    Revision History

    2026-06-01effectiveLatest

    Policy effective date set to 2026-06-01.

    2026-05-13last_review

    Committee review and last updated on 2026-05-13.

    2026-05-13next_review

    Next review scheduled on 2026-05-13.

    Policy Summary
    Payerpriority health
    PolicyGenetics: Counseling, Testing, Screening
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain electronic prior authorization through Evicore for tests listed as eC PA before billing.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Test CodesProvider Actions and Prior AuthorizationNot Covered — Exclusions and Explicit Non-CoverageDefinitions and BackgroundEligibility RequirementsCoding — Key Values & ConstraintsRevision History
    Prenatal diagnostic chromosomal/cytogenetic testing (amniocentesis or chorionic villus sampling) is medically necessary when genetic counseling has occurred and the indication for testing is documented. Common indications include abnormal fetal ultrasound findings; abnormal maternal serum screening (first trimester, triple/quad, integrated, elevated MSAFP); or increased risk based on documented family history or carrier status.
    Prenatal diagnostic chromosomal/cytogenetic testing is not medically necessary for sex determination unless medically indicated, for prenatal paternity determination, or for preconceptual testing of gametes/embryos for assisted reproduction when not covered by rider.
    Exclusions specific to rWGS: rWGS is not medically necessary for inpatient members whose clinical course is entirely explained by conditions such as infection/sepsis with normal response to therapy, isolated prematurity, isolated transient neonatal tachypnea, isolated unconjugated hyperbilirubinemia, hypoxic ischemic encephalopathy with clear precipitating event, meconium aspiration, previously confirmed genetic diagnosis that explains the condition, or trauma.
    rWGS is not medically necessary for inpatient members when clinical course is fully explained by non-genetic conditions listed in exclusions (eg, isolated prematurity, typical infection responding to therapy, confirmed prior genetic diagnosis, trauma, etc.).
  1. Several molecular pathology and genomic procedure codes (81404-81408, 81412-81415, 81419, 81425-81427, 81430-81441, 81460, etc.) are assigned eC PA, except select fetal aneuploidy panel 81420 (No PA required).
  2. Select U-codes for complex genomic tests, tumor profiling, transplant dd-cfDNA, pharmacogenomic panels, and MRD assays (eg, 0072U-0074U, 0088U, 0094U, 0118U, 0239U, 0242U, 0244U, 0246U, 0239U, 0306U-0307U, 0326U, 0327U, 0379U, 0388U, 0391U, 0473U-0475U, 0477U, 0481U, 0561U-0562U, etc.) are identified as eC PA. Some U-codes are explicitly Not Covered (eg, 0248U, 0249U, 0295U, 0301U, 0302U, 0295U).
  3. Certain tests are listed OOS for eC with no PA required for specified lines (eg, 0089U OOS for eC - No PA required for commercial; 81420 fetal aneuploidy—No PA required).
  4. Per-test coverage categories and special conditions

    • Bladder tumor antigen tests (eg, BTA Stat 86294, NMP22 86386) are covered only when the diagnosis codes indicate bladder neoplasm or history (eg, C67.0-C67.9, D09.0, D49.4, Z85.51) and are otherwise not covered for screening.
    • Some codes are explicitly Not Covered across lines of business (eg, many specialty U-codes for infectious or niche assays such as 0115U, 0192U-0195U, 0248U, 0249U, 0295U, 0301U, 0302U, 0323U, etc.).
    • Tests intended for tumor chemoresistance/chemosensitivity are Not Covered (see chemoresistance criteria) and specific U-codes (0248U, 0249U) are listed Not Covered.
    • When coverage is limited to specific diagnoses, the relevant ICD-10 codes must be present on the claim (eg, bladder antigen tests).
    Operational billing and documentation notes: Providers must supply documentation of counseling, informed consent, and clinical indications on request. Tests listed as Not Covered should not be billed; eC PA-required tests should have prior authorization obtained per Evicore/ eC workflows. Some codes require review in panels or 'Review in panels' — these are evaluated in the context of a panel and may require PA.
    Oncology tumor profiling and cfDNA assays (eg, 0239U, 0242U, 0244U, 0250U, 0326U, 0379U, 0388U, 0473U, 0562U) are designated eC PA; detailed coverage may depend on tumor type, indication, and whether test informs therapy selection or monitoring (eg, MRD).

    Coverage stance (eC PA vs Not Covered)

    • Codes marked eC PA: prior authorization required electronically; coverage approval depends on documentation of medical necessity per Evicore criteria and the specific clinical context.
    • Codes/Tests marked Not Covered: deemed experimental/investigational or not medically necessary for indicated uses and should not be billed; examples include certain infectious NGS assays, some niche U-codes, and tumor chemoresistance assays (see table).
    • Codes with 'Review in panels' status are evaluated in the context of a panel and may require eC PA or medical review prior to payment.
    Per-code coverage conditions: When a code requires a specific minimal gene set (eg, 81413 must include specified genes for cardiac ion channelopathies; 81439 must include DSG2, MYBPC3, MYH7, PKP2, TTN for inherited cardiomyopathy), the laboratory panel must meet the described minimum gene content to be considered for coverage. For tests limited to specific diagnoses (eg, bladder markers), the appropriate ICD-10 diagnosis must be present on the claim.

    Meaning of 'eC PA' and 'Review in panels'

    'eC PA' next to a code indicates the payer requires electronic prior authorization through Evicore; codes labeled 'Review in panels' are subject to panel-level review and medical necessity assessment rather than standalone coverage.

    Prior Authorization

    Electronic prior authorization or panel review required

    Many tests in the tables are labeled 'eC PA' or 'Review in panels' for Commercial, Medicaid, and Priority Medicare; providers must obtain electronic prior authorization or complete the panel review process before performing or billing these services.

    Prior Authorization

    Obtain PA before billing eC PA or panel‑review codes

    Providers must submit prior authorization via Evicore for CPT/PLA codes that are designated 'eC PA' before billing; orders for codes marked 'Review in panels' should follow panel-review initiation per Evicore guidance.

    Note

    Summary: many codes require prior authorization

    Across the coding tables many CPT and PLA/HCPCS codes are annotated as requiring prior authorization ('eC PA') for the indicated plan types; confirm PA requirements for each code in Section VI prior to ordering.

    Prior Authorization

    eC PA required before billing

    Tests listed with 'eC PA' require electronic prior authorization through Evicore prior to service and billing; do not bill these services without approved PA for the applicable plan.

    Prior Authorization

    Verify PA requirement for listed codes

    Numerous codes in the tables are annotated 'eC PA' indicating prior authorization is required; verify and obtain Evicore PA for the specific U/CPT code and member plan before performing the test.

    Prior Authorization

    Routine eC PA for many listed tests

    Tests in the listed CPT ranges are frequently marked 'eC PA'; providers must request and receive Evicore electronic prior authorization for those tests under the applicable plan prior to testing and billing.

    Prior Authorization

    eC PA required for many U‑codes

    Many U‑codes in the PLA listings show 'COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA' — if the ordered U‑code is so annotated, obtain Evicore electronic clinical prior authorization before service.

    Prior Authorization

    Electronic case‑by‑case prior authorization required

    Some tests require electronic case‑by‑case prior authorization (eC PA) for coverage under Commercial, Medicaid, and Priority Medicare; providers should submit PA requests through Evicore for these entries prior to service.

    Prior Authorization

    PA and evidence review required for PLA/HCPCS tests

    PLA/HCPCS-coded tests annotated 'eC PA' are covered only after evidence review and prior authorization; submit Evicore PA and supporting documentation per the code entry before performing the test.

    Prior Authorization

    Obtain eC PA for listed PLA/U‑codes

    Many PLA/HCPCS and U‑code entries are annotated 'eC PA' indicating electronic clinical prior authorization is required before services are rendered or billed for the listed plans.

    Prior Authorization

    U‑codes require eC PA across plans

    Multiple U‑codes show 'COMMERCIAL PLANS = eC PA. MEDICAID = eC PA. PRIORITY MEDICARE = eC PA.' — providers must obtain Evicore electronic prior authorization for these U‑codes across plan types prior to testing.

    Prior Authorization

    G9143 requires prior authorization

    Warfarin responsiveness testing (G9143) is designated eC PA and requires prior authorization through Evicore for Commercial, Medicaid, and Priority Medicare before service.

    Documentation Required

    Obtain informed consent and document genetic counseling

    Documented informed consent must occur before testing and pre‑ and post‑test genetic counseling must be provided and documented; for specified conditions counseling must be by a board‑certified genetic counselor independent of the testing laboratory.

    • Counseling may occur at same visit if documentation meets requirements
    • Michigan informed consent law applies (Mich. Comp. Laws 333.17020)
    Documentation Required

    Include medical necessity and counseling documentation with PA/claims

    When submitting authorization or claims, include documentation supporting medical necessity (diagnosis, clinical rationale) and document genetic counseling; CPT/HCPCS counseling codes 96041 and S0265 are available when criteria are met.

    • Include clinical rationale and relevant diagnosis codes with PA/claim
    • Use 96041 or S0265 when counseling is provided
    Documentation Required

    Include test description, vendor alias, and indication with PA/claims

    PA/panel-review actions are indicated per code in the table (eC PA, Review in panels, Not Covered); providers should include documentation (test description, vendor/test alias, clinical indication, and relevant diagnosis codes) to support PA or billing.

    • Include the vendor/test alias as shown in the code table when available
    • Document the clinical indication and matching diagnosis codes
    Billing Rule

    Attach explanatory notes for unlisted codes (81479, 81599, 84999)

    For unlisted molecular pathology (81479) and other unlisted codes (81599, 84999) include explanatory notes identifying the specific test and details sufficient for review when submitting the claim or PA request.

    • Attach explanatory notes identifying the specific assay and vendor/lab
    • Provide clinical rationale and documentation of medical necessity
    Documentation Required

    Include test description and laboratory alias with requests

    Each code entry includes a brief description and example vendor/test alias; include the test description and alias/laboratory when requesting prior authorization or submitting claims to support medical necessity.

    Documentation Required

    Document diagnosis codes for diagnosis‑restricted tests

    Some tests are covered only for specific diagnoses (for example, 0471U is covered for colorectal cancer diagnoses C18.0–C18.5); document the listed diagnosis code(s) on the PA request and claim.

    • For 0471U include diagnosis C18.0–C18.5 as applicable
    Billing Rule

    Provide explanatory notes for other unlisted codes (88299, 89240, 88399)

    For unlisted cytogenetic/pathology procedure codes (88299, 89240, 88399, etc.) include explanatory notes identifying the specific test and relevant details with the claim or PA submission.

    Note
    Denial Risk

    Denial risk for missing Evicore PA or panel review

    Failure to obtain required Evicore prior authorization or to complete required panel review for codes marked 'eC PA' or 'Review in panels' may result in claim denial.

    Prior Authorization

    Initiate Evicore PA using the panel code that requires PA

    If any procedure code in a multi‑test panel requires prior authorization, that procedure code should initiate the Evicore PA workflow; failure to submit the required PA for the triggering code may lead to denial of the panel.

    Note
    Denial Risk

    Not‑covered tests will be denied if billed

    Tests labeled 'Not Covered' for the member's line of business (Commercial, Medicaid, Priority Medicare) will be denied if billed for that plan; confirm plan‑level coverage status before ordering.

    • Examples: multiple U‑codes and CPT entries are explicitly marked Not Covered in the tables
    Note

    Panel‑level review may be required for 'Review in panels' codes

    Some single‑gene tests and other entries are annotated 'Review in panels' — these require panel‑level review prior to coverage decisions; if included in a multi‑test panel, panel rules apply and PA must be initiated as noted.

    Note

    No prior authorization required for 81420 (NIPT common aneuploidies)

    Code 81420 (fetal chromosomal aneuploidy cfDNA NIPT) is designated 'No PA required' for Commercial, Medicaid, and Priority Medicare; do not initiate Evicore PA for 81420.

    Denial Risk

    Billing Not Covered tests risks denial and patient liability

    Tests explicitly labeled 'Not Covered' in the tables will trigger claim denials when billed for the specified plan(s); review the Not Covered entries before ordering and consider alternative testing or patient financial responsibility discussions.

    Denial Risk

    Not Covered entries and benefit‑rider exceptions may trigger denials

    Tests marked 'Not Covered' or otherwise unsupported for the member's plan (e.g., codes listed as Not Covered for Medicaid or Priority Medicare) are denial triggers; verify plan status and benefit riders (e.g., Fertility Rider) before ordering.

    • 89290/89291 covered only with Fertility Rider for commercial plans; Not Covered for Medicaid and Priority Medicare
    Denial Risk

    Failure to obtain eC PA may cause denial

    Many tests labeled 'eC PA' require electronic clinical prior authorization; failure to obtain Evicore authorization prior to service may result in denial for Commercial, Medicaid, and Priority Medicare plan members.

    Denial Risk

    Not Covered codes for benefit types will be denied absent rider

    Codes marked 'Not Covered' for specific benefit types (for example, 89290/89291 Not Covered for Medicaid and Priority Medicare) will be denied when billed unless coverage conditions (such as a Fertility Rider) apply.

    Several additional tests across the U‑code windows and traditional CPT ranges are explicitly marked Not Covered. Examples in the document include lab and cytology codes such as 86352 (cellular function assays) and 88130 (sex chromatin/Barr body identification), both shown with Not Covered status in the coding tables.

    The policy lists many specific U‑codes (for example 0078U, 0086U, 0112U, 0115U, 0152U, 0177U) and multiple red cell antigen genotyping codes as Not Covered for the designated plan types. These entries serve as explicit examples of codes that will not be reimbursed when billed under plans that list them as Not Covered.

    Examples of U‑codes explicitly labeled Not Covered include 0238U, 0248U, 0249U, 0295U, 0301U, and 0302U — each of which is shown with a Not Covered payer disposition for one or more lines of business in the tables.

    The coding listings include additional Not Covered examples such as 0310U (Kawasaki biomarker panel), 0323U (metagenomic NGS for CNS pathogens), and 0328U (large urine drug assay); these are explicitly marked Not Covered for the indicated plan types in the policy tables.

    Specific PLA/HCPCS entries are flagged as Not Covered for one or more plan types — for instance, 0407U and 0429U are listed as Not Covered in the coding tables. Providers should reference the table to determine whether a given PLA code is payable for the member's plan.

    A group of tests (for example 0490U, 0491U, 0492U, 0511U, 0512U, 0513U, 0532U, 0502U, 0500U) are explicitly shown as Not Covered across Commercial, Medicaid, and Priority Medicare in the document; these entries are examples of codes that will be denied if billed under the listed plan types.

    The policy lists reproductive and embryo testing codes (such as PGT‑SR/PGT‑A entries 0555U, 0553U, 0554U and related PLA codes) with coverage notes; some reproductive testing codes are Not Covered unless a Fertility Rider is present. The table provides explicit per‑code descriptions and coverage dispositions that should be used to determine medical necessity and billing appropriateness.

    Individual tests and CPT codes are designated Not Covered or OOS in the coding listings. For example, 0614U is Not Covered for Medicaid and Priority Medicare, and multiple traditional CPT lab codes are shown as OOS or Not Covered. Check the code table for plan‑specific dispositions before billing.

    Pre‑implantation genetic diagnosis biopsy procedures (CPT 89290 and 89291) are covered only when the member has purchased a Fertility Rider for commercial plans and are Not Covered for Medicaid and Priority Medicare. The Fertility Rider requirement must be documented to support coverage.

    The coding tables list multiple additional codes and test types as Not Covered (for example, 86352 — cellular function assay — and 88130 — sex chromatin/Barr body identification). These specific code entries are shown with payer dispositions indicating they are excluded from coverage.

    Whole genome sequencing (WGS) / rapid WGS (rWGS)
    DefinitionWhole genome sequencing (WGS): laboratory procedure that determines an individual's entire DNA sequence (order of every base pair across the genome).
    Rapid WGS (rWGS)A high-speed form of WGS that shortens analysis time; may be medically necessary for acutely ill inpatients when ordered after a Board‑Certified/Board‑Eligible Medical Geneticist determines it could inform diagnosis/treatment.
    Clinical role and limitationsRole in the clinical setting is evolving; interpretation of variants and relationship to disease is still being analyzed.
    Review in Panels — meaning
    DefinitionReview in Panels: code-level annotation indicating the test is reviewed at the panel level (panel coverage determination) rather than solely as an individual procedure code.
    Implication for multi-test panelsIf a code is reported within a multi‑procedure panel and any included code requires PA, panel review or the PA‑required code should initiate Evicore prior authorization.
    Coverage outcomeCoverage depends on panel review outcome; review may be requested even if PA not routinely required for the individual code.
    eC PA — electronic prior authorization (Evicore)
    DefinitioneC PA = electronic prior authorization processed through Evicore (payer's electronic prior authorization workflow).
    When usedUsed as the coverage annotation next to many CPT/PLA/U‑codes to indicate that electronic prior authorization is required before services are rendered or billed.
    Provider actionProviders must submit PA requests via Evicore portal for codes annotated 'eC PA'; failure to obtain PA may result in denial.
    Unlisted procedure codes and documentation
    Codes81599 (Unlisted multianalyte assay with algorithm) and 84999 (Unlisted chemistry procedure) represent unlisted tests not otherwise specified.
    Claim requirementExplanatory notes identifying the specific test must accompany claims for 81599 and 84999 (and other unlisted codes) to support medical necessity and allow adjudication.
    PA annotationThese unlisted codes are annotated 'COMMERCIAL PLANS = eC PA' (and similarly for Medicaid/Priority Medicare), so submit explanatory documentation with PA as applicable.
    Alias / Test Name (Lab) — vendor examples
    PurposeAlias/Test Name (Lab) provides example vendor or commercial test names linked to a code (e.g., miR‑31now for 0069U; Genomic Unity/Variantyx examples for WGS entries).
    Use in submissionsInclude the vendor/test alias (example lab name) in authorization/billing documentation to clarify which proprietary or LDT is being requested.
    Not exhaustiveAlias lists are illustrative and not all‑inclusive; provider should state the performing lab and test version when submitting PA or claims.
    Coverage annotations — meanings
    eC PAIndicates electronic clinical prior authorization is required before coverage will be considered (submit via Evicore portal).
    Not CoveredIndicates the payer will not reimburse the service for the specified plan(s); such tests should not be billed as covered services (examples listed per code).
    OOS / No PA required'OOS for eC - No PA' or 'No PA required' indicates the test is out‑of‑scope for Evicore management and may be billed without prior Evicore PA for that line of business.
    eC PA — electronic clinical prior authorization (definition)
    DefinitionElectronic clinical prior authorization (eC PA): tests that require prior authorization via the payer's electronic workflow before services are rendered/billed.
    Plan-level applicationMany U‑codes and CPT codes are annotated 'COMMERCIAL PLANS = eC PA' and similarly for Medicaid/Priority Medicare; follow the listed PA process per plan.
    DocumentationFor eC PA submissions include clinical rationale and any required diagnostic codes, test description, and vendor/test alias to support medical necessity.
    OOS for eC — No prior authorization required (plan exceptions)
    OOS/No PA for certain codesSome tests and CPTs are marked 'OOS for eC - No PA' or 'No PA required' for specific plan lines (examples: 86386 NMP22 and certain cytology/flow codes), meaning prior authorization via Evicore is not required for those plan(s).
    Plan exceptionsOOS designation may be plan‑ and code‑specific (verify the listed disposition for Commercial, Medicaid, and Priority Medicare).
    Billing noteEven when No PA is required, providers must still document medical necessity and use the listed diagnosis codes where coverage is diagnosis‑limited (see per‑code notes).
    Whole‑genome sequence analysis — technical definition
    DefinitionWhole‑genome sequence analysis: combination of short and long reads to detect single nucleotide variants (SNVs), insertions/deletions (indels), characterized intronic variants, copy‑number variants (CNVs), duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, inversions, mitochondrial DNA variants, short tandem repeats, and selected methylation regions.
    SpecimensPerformed on blood, saliva, amniocentesis, chorionic villus sample, or tissue depending on clinical context and code description.
    Alias/exampleDescriptive aliases (e.g., Genomic Unity® 2.0, Variantyx) appear in code entries to indicate example implementations of whole‑genome analyses.
    PGT‑SR / embryonic aneuploidy testing — definition
    DefinitionPGT‑SR / embryonic aneuploidy testing: genetic assessment of 24 chromosomes from embryonic trophectoderm to detect structural rearrangements, aneuploidy, ploidy, mitochondrial DNA score and embryo quality; results per embryo include euploid/balanced, unbalanced rearrangement, monosomy, trisomy, mosaic, etc.
    Example code0555U is described for PGT‑SR with per‑embryo reporting and quality control metrics; many PGT codes are annotated eC PA in the listing.
    Coverage conditionPreimplantation biopsy CPTs (89290/89291) have separate coverage rules — commercial coverage only with a Fertility Rider; Medicaid and Priority Medicare = Not Covered.
    Diagnosis‑limited coverage examples
    Example — diagnosis‑limited coverage86386 (NMP22) is covered only when the diagnosis is one of: C67.0–C67.9, D09.0, D49.4, or Z85.51 (bladder neoplasm/history).
    UroVysion FISH88120/88121 (UroVysion) are covered only for malignant neoplasm of the bladder (C67.0–C67.9, D09.0, D49.4, Z85.51) and are OOS for eC — No PA required in those settings.
    Documentation requiredClaim submissions for diagnosis‑limited tests must include the listed diagnosis code to support coverage.
    Fertility Rider requirement for pre‑implantation biopsy codes
    Codes89290 and 89291: embryo/oocyte biopsy for pre‑implantation genetic diagnosis (PGD).
    Coverage conditionCovered for Commercial plans only when the member has a Fertility Rider; Medicaid and Priority Medicare: Not Covered.
    Billing implicationDo not bill as covered under Medicaid or Priority Medicare; for Commercial coverage include evidence of Fertility Rider eligibility in PA/claim submission.
    All procedure codes (81105–81599) included in a multiple‑procedure panel are subject to medical necessity review if any code requires PA.
    Practical implicationProviders should identify the PA‑triggering code when submitting Evicore requests for multi‑test panels to avoid denials.
    Minimum gene counts required for panel CPT codes
    Panel minimum gene countsSome CPT panel codes specify minimum gene counts (examples: 81410 >=9 genes; 81413 >=10 genes; 81415 = exome; 81418 >=6 genes; 81430 >=60 genes; 81440 >=100 genes).
    Code matching requirementA panel must include the required named genes and meet the minimum gene count to correspond to the listed CPT panel code description.
    DocumentationSubmit panel gene list or laboratory documentation showing included genes to support code selection during PA/claim submission.
    Panel gene count requirement examples
    Examples of gene‑count thresholdsExamples include: >=5 genes (e.g., 81439, 81448); >=12 genes (81442); >=15 genes (81443); >=30 genes (81441); >=51 genes (81455/81456).
    Panel type implicationPanel codes are stratified by gene count and intended clinical context (cardiomyopathy, Noonan, IBMFS, oncology panels, etc.).
    Provider actionEnsure the laboratory panel meets the code's listed gene count and named gene requirements when requesting PA or billing.
    Gene counts per test — examples
    Varied gene counts per testTest descriptions list a range of panel sizes and gene counts (examples in document include 8‑protein assays, 92‑gene, 112‑gene, 161‑gene, 324‑gene, 468‑gene panels and larger cfDNA panels of 311+ genes).
    Check per‑code descriptionProviders should reference the specific code's description for the exact gene count or content requirement when ordering and requesting PA.
    Examples of very large panelsCodes such as FoundationOne Liquid CDx (0239U) and other comprehensive panels list 311+ or 257/505 gene counts in entries.
    Gene counts — explicit numeric examples
    Explicit numeric valuesThe policy lists explicit numeric panel sizes in many descriptions (examples: 311+, 55–74, 257, 505, 238, 112, 74, 35, 40, 24).
    Use in coverage determinationThese explicit panel sizes are part of the code description and inform whether a given laboratory test maps to the code for PA and coverage decisions.
    Provider instructionInclude test panel size and gene list in PA request to demonstrate correspondence with the CPT/PLA code description.
    Covered diagnoses required for 0471U
    Covered diagnoses for 0471UC18.0, C18.1, C18.2, C18.3, C18.4, C18.5 (qualifying colorectal cancer diagnoses for coverage of 0471U under Commercial Plans).
    Provider actionWhen ordering 0471U, include one of the listed diagnosis codes on the PA/claim to meet the code's diagnosis‑limited coverage condition.
    Plan applicabilityThis diagnosis restriction is specified for Commercial Plans in the code entry; verify Medicaid/Priority Medicare disposition as listed.
    Gestational age for fetal RhD PCR (0536U)
    Gestational age thresholdFetal RhD PCR (0536U) is indicated for maternal blood specimens at gestational age >= 10 weeks.
    Code annotation0536U is annotated 'COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA' in the listing.
    Provider noteConfirm laboratory‑validated gestational age window when requesting PA for fetal RhD testing and include GA in documentation.
    Number of methylation sites reported — examples
    Methylation site counts — examplesPolicy lists number of methylation sites reported for assays as ranges or explicit counts (examples: >20,000 sites, >30,000 sites, >5,000 sites, 6,626 sites for certain HCC methylation tests).
    Test mappingRefer to the specific U‑code description for the exact number of methylation regions assayed when submitting PA or claims.
    DocumentationInclude assay description and site count in PA request to support the selected code mapping and medical necessity review.
    FISH probe / cell analysis thresholds (CPT examples)
    FISH/cell analysis thresholdsExamples in policy for FISH/interphase cell counts: 88272 (analyze 3–5 cells), 88273 (10–30 cells), 88274 (25–99 cells), 88275 (100–300 cells).
    Coding implicationSelect the appropriate FISH CPT based on the number of cells analyzed per the laboratory procedure and include that detail in documentation.
    No PA requiredThese FISH/Cytogenetics codes are shown as OOS for eC — No PA required in many plan entries; verify per‑code disposition before submission.
    Chromosome analysis cell counts — examples
    Chromosome analysis cell counts — examplesPolicy gives example CPT chromosome analysis counts: 88261 = count 5 cells; 88262 = count 15–20 cells; 88263 = count 45 cells for mosaicism; 88264 = analyze 20–25 cells.
    Implication for codingChoose the chromosome analysis CPT that matches the laboratory's cell‑count methodology; include counts in documentation when appropriate.
    PA statusThese chromosome analysis CPTs are listed OOS for eC — No PA required for many plan types, but verify per code before billing.